Kinetics of cytomegalovirus (CMV) pp65 and IE-1-specific IFNγ CD8+ and CD4+ T cells during episodes of viral DNAemia in allogeneic stem cell transplant recipients: Potential implications for the management of active CMV infection
Nuria Tormo
Microbiology Service, Clinic University Hospital, Valencia, Spain
Search for more papers by this authorCarlos Solano
Hematology and Medical Oncology Service, Clinic University Hospital, Valencia, Spain
Department of Medicine, School of Medicine, University of Valencia, Valencia, Spain
Search for more papers by this authorIsabel Benet
Hematology and Medical Oncology Service, Clinic University Hospital, Valencia, Spain
Search for more papers by this authorJosé Nieto
Hematology Service, Morales Meseguer Hospital, Murcia, Spain
Search for more papers by this authorRafael de la Cámara
Hematology Service, La Princesa Hospital, Madrid, Spain
Search for more papers by this authorAna Garcia-Noblejas
Hematology Service, La Princesa Hospital, Madrid, Spain
Search for more papers by this authorMaría Ángeles Clari
Microbiology Service, Clinic University Hospital, Valencia, Spain
Search for more papers by this authorMarifina Chilet
Microbiology Service, Clinic University Hospital, Valencia, Spain
Search for more papers by this authorJavier López
Hematology Service, Ramón Cajal Hospital, Madrid, Spain
Search for more papers by this authorJuan Carlos Hernández-Boluda
Hematology and Medical Oncology Service, Clinic University Hospital, Valencia, Spain
Search for more papers by this authorMaría José Remigia
Hematology and Medical Oncology Service, Clinic University Hospital, Valencia, Spain
Search for more papers by this authorCorresponding Author
David Navarro
Microbiology Service, Clinic University Hospital, Valencia, Spain
Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain
Department of Microbiology, School of Medicine, Av. Blasco Ibáñez 17, 46010 Valencia, Spain.===Search for more papers by this authorNuria Tormo
Microbiology Service, Clinic University Hospital, Valencia, Spain
Search for more papers by this authorCarlos Solano
Hematology and Medical Oncology Service, Clinic University Hospital, Valencia, Spain
Department of Medicine, School of Medicine, University of Valencia, Valencia, Spain
Search for more papers by this authorIsabel Benet
Hematology and Medical Oncology Service, Clinic University Hospital, Valencia, Spain
Search for more papers by this authorJosé Nieto
Hematology Service, Morales Meseguer Hospital, Murcia, Spain
Search for more papers by this authorRafael de la Cámara
Hematology Service, La Princesa Hospital, Madrid, Spain
Search for more papers by this authorAna Garcia-Noblejas
Hematology Service, La Princesa Hospital, Madrid, Spain
Search for more papers by this authorMaría Ángeles Clari
Microbiology Service, Clinic University Hospital, Valencia, Spain
Search for more papers by this authorMarifina Chilet
Microbiology Service, Clinic University Hospital, Valencia, Spain
Search for more papers by this authorJavier López
Hematology Service, Ramón Cajal Hospital, Madrid, Spain
Search for more papers by this authorJuan Carlos Hernández-Boluda
Hematology and Medical Oncology Service, Clinic University Hospital, Valencia, Spain
Search for more papers by this authorMaría José Remigia
Hematology and Medical Oncology Service, Clinic University Hospital, Valencia, Spain
Search for more papers by this authorCorresponding Author
David Navarro
Microbiology Service, Clinic University Hospital, Valencia, Spain
Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain
Department of Microbiology, School of Medicine, Av. Blasco Ibáñez 17, 46010 Valencia, Spain.===Search for more papers by this authorAbstract
The dynamics of CMV pp65 and IE-1-specific IFNγ-producing CD8+ (IFNγ CD8+) and CD4+ (IFNγ CD4+) T cells and CMV DNAemia were assessed in 19 pre-emptively treated episodes of active CMV infection. Peripheral counts of IFNγ CD8+ and IFNγ CD4+ T cells inversely correlated with CMV DNAemia levels (P = <0.001 and P = 0.003, respectively). A threshold value of 1.3 cells/µl predicting CMV DNAemia clearance was established for IFNγ CD8+ T cells (PPV, 100%; NPV, 93%) and for IFNγ CD4+ T cells (PPV, 100%; NPV, 75%). Undetectable T-cell responses were usually observed at the time of initiation of pre-emptive therapy. Either a rapid (within 7 days) or a delayed (median 31 days) expansion of both T-cell populations concomitant with CMV DNAemia clearance was observed in 5 and 8 episodes, respectively. An inconsistent or a lack of expansion of both T-cell subsets was related to a persistent CMV DNAemia. Robust and maintained CMV-specific T-cell responses after CMV DNAemia clearance and cessation of antiviral therapy were associated with a null incidence of relapsing infections at least during the following month. Data obtained in the present study may be helpful in the design of therapeutic strategies for the management of active CMV infections in the allo-SCT recipient. J. Med. Virol. 82: 1208–1215, 2010. © 2010 Wiley-Liss, Inc.
REFERENCES
- Aubert G, Hassan-Walker AF, Madrigal AJ, Emery VC, Morte C, Grace S, Koh MB, Potter M, Prentice HG, Dodi IA, Travers PJ. 2001. Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants. J Infect Dis 184: 955–963.
- Avetiyan G, Larsson K, Aschan J, Nilsson C, Hassan M, Ljungman P. 2006. Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogenic stem cell transplantation. Bone Marrow Transplant 38: 687–692.
- Avetisyan G, Aschan J, Hägglund H, Ringdén O, Ljungman P. 2007. Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. Bone Marrow Transplant 40: 865–869.
- Boeckh M, Nichols WG, Papanicolau G, Rubin R, Wingard JR, Zaia J. 2003. Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol Blood Marrow Transplant 9: 543–558.
- Eid AJ, Brown RA, Hogan WJ, Lahr BD, Eckel-Passow JE, Litzow MR, Razonable RR. 2009. Kinetics of interferon-gamma producing cytomegalovirus (CMV)-specific CD4+ and CD8+ lymphocytes and the risk of subsequent CMV viremia after allogeneic hematopoietic stem cell transplantation. Transplant Infect Dis 11: 519–528.
- Einsele H, Kapp M, Grigoleit GU. 2008. CMV-specific T-cell therapy. Blood Cells Mol Dis 40: 71–75.
- Foster AE, Gottlieb DJ, Sartor M, Hertzberg MS, Bradstock KF. 2002. Cytomegalovirus-specific CD4+ and CD8+ T-cells follow a similar reconstitution pattern after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 8: 501–511.
- Gimeno C, Solano C, Latorre JC, Hernández-Boluda JC, Clari MA, Remigia MJ, Furió S, Calabuig M, Tormo N, Navarro D. 2008. Quantification of DNA in plasma by an automated real-time PCR assay (CMV PCR Kit, Abbott) for surveillance of active cytomegalovirus infection and guidance of pre-emptive therapy for allogeneic hematopoietic stem cell transplant recipients. J Clin Microbiol 46: 3311–3318.
- Gratama JW, Brooimans RA, van der Holt B, Sintnicolaas K, van Doornum G, Niesters HG, Löwenberg B, Cornelissen JJ. 2008. Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations. Cytometry Part B 74B: 211–220.
- Griffiths P, Whitley R, Snydman DR, Singh N, Boeckh M. 2008. Contemporary management of cytomegalovirus infection in transplant recipients: Guidelines from an IHMF workshop, 2007. Herpes 15: 1–12.
- Hakki M, Riddell SR, Storek J, Carter RA, Stevens-Ayers T, Sudour P, White K, Corey L, Boeckh M. 2003. Immune reconstitution to cytomegalovirus after allogeneic stem cell transplantation: Impact of host factors, drug therapy, and subclinical reactivation. Blood 102: 3060–3067.
- Hebart H, Daginik S, Stevanovic S, Grigoleit U, Dobler A, Baur M, Rauser G, Sinzger C, Jahn G, Loeffler J, Kanz L, Rammensee HG, Einsele H. 2002. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-γ enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood 99: 3830–3837.
- Lilleri D, Fornara C, Chiesa A, Caldera D, Alessandrino EP, Gerna G. 2008. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Haematologica 93: 248–256.
- Ljungman P. 2006. Would monitoring CMV immune responses allow improved control of CMV in stem cell transplant patients? J Clin Virol 35: 493–495.
- Ljungman P. 2008. CMV infections after hematopoietic stem cell transplantation. Bone Marrow Transplant 42: S70–S72.
- Moins-Teisserenc H, Busson M, Scieux C, Bajzik V, Cayuela JM, Clave E, de Latour RP, Agbalika F, Ribaud P, Robin M, Rocha V, Gluckman E, Charron D, Socié G, Toubert A. 2008. Patterns of cytomegalovirus reactivation are associated with distinct evolutive profiles of immune reconstitution after allogeneic hematopoietic stem cell transplantation. J Infect Dis 198: 818–826.
- Ohnishi M, Sakurai T, Heike Y, Yamazaki R, Kanda Y, Takaue Y, Mizoguchi H, Kawakami Y. 2005. Evaluation of cytomegalovirus-specific T-cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon- gamma-enzyme-linked immunospot and human leucocyte antigen tetramer assays with an immunodominant T-cell epitope. Br J Haematol 131: 472–479.
- Pourgheysari B, Piper KP, McLarnon A, Arrazi J, Bruton R, Cook M, Mahendra P, Craddock C, Moss PAH. 2009. Early reconstitution of effector memory CD4+ CMV-specific T cells protects against CMV reactivation following allogeneic SCT. Bone Marrow Transplant 43: 853–861.
- Quinnan GV, Kirmani N, Rook AH, Manischewitz JF, Jackson L, Moreschi G, Santos GW, Saral R, Burns WH. 1982. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med 307: 7–13.
- Reusser P, Riddell SR, Meyers JD, Greenberg PD. 1991. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78: 1373–1380.
- Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. 1992. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257: 238–241.
- Solano C, Muñoz I, Gutiérrez A, Farga A, Prósper F, García-Conde J, Navarro D, Gimeno C. 2001. Qualitative plasma assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding pre-emptive ganciclovir therapy in allogeneic stem cell transplantation. J Clin Microbiol 39: 3938–3941.
- Solano C, Benet I, Clari MA, Nieto J, de la Cámara R, López J, Hernández-Boluda JC, Remigia MJ, Jarque I, Calabuig ML, Garcia-Noblejas A, Alberola J, Tamarit A, Gimeno C, Navarro D. 2008. Enumeration of CMV-specific IFNγ CD8+ and CD4+ T cells early after allogeneic stem cell transplantation may identify patients at risk of active CMV infection. Haematologica 93: 1434–1436.
- Tormo N, Solano C, Benet I, Clari MA, Nieto J, de la Cámara R, López J, López-Aldeguer N, Hernández-Boluda JC, Remigia MJ, Garcia-Noblejas A, Gimeno C, Navarro D. 2010. Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8(+) and CD4(+) T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 45: 543–549.
- Widmann T, Sester U, Gärtner BC, Schubert J, Pfreundschuh M, Köhler H, Sester M. 2008. Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation. PLoS ONE 3: 1–12.